PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9777897

Platelet refractoriness and alloimmunization.

S J Slichter
View original source ↗Export metadata ↓

Abstract

The two major methods of modifying donor blood products to prevent alloimmunization are leukocyte reduction or ultraviolet B (UVB) irradiation. Two studies have suggested that leukocyte reduction to levels <5 x 10(6) may be required to prevent alloantibody production. Three prospective, randomized transfusion trials demonstrated a statistically significant (P < 0.05) decrease in both platelet refractoriness and lymphocytotoxic antibody production in patients who received leukocyte-reduced blood components as compared to those who received standard unmodified blood products. The results of the Trial to Reduce Alloimmunization to Platelets (TRAP trial) further confirm the potential beneficial effects of leukocyte-reduced and UVB-irradiated blood products in preventing alloimmune platelet refractoriness. Five hundred thirty antibody-negative patients undergoing induction chemotherapy for acute myeloid leukemia were randomly assigned to receive either unmodified platelet concentrates, filtered leukocyte-reduced platelet concentrates, UVB-irradiated platelet concentrates, or filtered leukocyte-reduced platelets obtained by apheresis. Patients who received modified platelet components had statistically significantly lower rates of both alloimmune platelet refractoriness and lymphocytotoxic antibodies than did patients who received unmodified platelet components. There were no differences in any study endpoints among patients who received any of the three modified platelet components. The investigators concluded that leukocyte-reduced and UVB-irradiated platelet components were equally effective in preventing alloimmune-mediated platelet refractoriness; platelets obtained by apheresis provided no additional benefit.

Explore related subjects

Antibody FormationBlood Component TransfusionBlood PlateletsCell SeparationHumansIsoantibodiesLeukocytesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S J Slichter. 1998. Platelet refractoriness and alloimmunization.. https://pubmed.ncbi.nlm.nih.gov/9777897/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder.

BACKGROUND: The genetic basis for control of alloantibody responses against foreign HLA histocompatibility antigens has never been delineated. The most likely postulate would be that HLA class II alloantigens of the host regulate the response through their ability to present processed HLA allopeptide fragments for the cognate interaction between CD4+ T lymphocytes and B lymphocytes that leads to IgG antibody synthesis. METHODS: We have analyzed our allosensitized transplant patient population with regard to humoral responsiveness to a serologically defined public HLA class I epitope, Bw4. Peptides representing the linear sequence of the Bw4 epitope (amino acids 74-86) and the alternative Bw6 epitope were synthesized and assayed for binding to a panel of HLA homozygous lymphoblastoid B cells using a quantitative fluorescence binding assay. RESULTS: We found that 73% of patients who have produced a HLA-Bw4-specific alloantibody express either the HLA-DRB1*01 or HLA-DRB1*03 alloantigen; 19% of the remaining responders expressed HLA-DRB1*04. Analysis of the United Network for Organ Sharing Transplant Registry indicated that the survival of cadaver renal allografts mismatched for Bw4 was significantly compromised in sensitized DRB1*01+ or DRB1*03+ recipients (P<0.01). In vitro, the Bw4 peptide bound strongly to DRB1*01+ and DRB1*03+ lymphoblastoid B cells; no similar binding was observed with Bw6 peptide. These findings were confirmed using murine fibroblast lines transfected with HLA-DR alpha/beta genes and by solid-phase enzyme-linked immunosorbent assay using purified HLA-DR alloantigen. CONCLUSIONS: We conclude that there are at least two human Ir genes, HLA-DRB1*01 and HLA-DRB1*03, that confer a high risk for both humoral allosensitization and renal allograft failure in situations of HLA-Bw4 incompatibility. These findings may be of future benefit in devising new antigen matching strategies for reducing the risk of humoral HLA allosensitization and chronic allograft rejection.

Antibody Formation↗
PubMed1999

[Post-vaccination immunity after allogenic and autologous bone marrow transplantation].

In the submitted review the author describes time correlation's of reconstitution of immunity during the post-transplantation period in patients after autologous and allogeneic bone marrow transplantations. The authors presents values of different immunological parameters incl. functional examinations of immunity by the method of blastic lymphocyte transformation after stimulation with mitogens and vaccination antigens during the post-transplantation period. She also evaluates mechanisms involved in this process. An illustrative idea on the character and degree of affection of immunity mechanisms after bone marrow transplantation is provided by the state of postvaccination immunity after immunization made before the disease and bone marrow transplantation. The titres of postvaccination antibodies after a 1-4-year interval following bone marrow transplantation gradually drop to low or zero values. The author emphasises therefore the necessity of revaccination of patients with killed vaccines against tetanus, diphtheria, poliovirus and pneumococcal, meningococcal and haemophil infection during the post-transplantation period. Recommended vaccination patterns are also presented.

Antibody Formation↗